Out of 990 compensation claims related to the COVID-19 vaccine received by the Norwegian Patient Injury Compensation (NPE) by the end of 2022, 187 cases, or 19%, were related to the Vaxzevria vaccine from AstraZeneca.
Despite being used for only four weeks and accounting for only 1.2% of all doses administered in Norway, the vaccine has been linked to a higher incidence of low platelets and blood clots in the brain.
AstraZeneca has declined to comment on the figures. 41% of the claims were related to the Pfizer vaccine, and 19% were related to the Moderna vaccine.